Mounjaro vs. Wegovy: what the head-to-head data actually shows

What's this video probably claiming?

Based on the caption and hashtag context, @mindfulmilesjourney is almost certainly walking viewers through a comparison of tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy) as weight-loss injections, likely framing one as superior or helping followers decide which to ask their doctor about. These creator-versus comparisons are enormously popular in the GLP-1 space right now, and they tend to follow a predictable script: mechanism thumbnail, side-effect rundown, before-and-after weight loss percentages, and a soft lean toward whichever drug the creator happens to be using. With 441K views, this video has reached enough people that the framing matters. The problem is that most of these comparisons flatten genuinely complex clinical differences into a tidy winner-loser narrative, which does viewers a disservice when the actual trial data is considerably more textured than that.

What does the science actually show?

The most relevant direct evidence comes from the SURMOUNT-5 trial (Jastreboff et al., 2025, New England Journal of Medicine), which is the first head-to-head randomized controlled trial comparing tirzepatide 10mg or 15mg against semaglutide 2.4mg weekly in adults with obesity but without diabetes. At 72 weeks, tirzepatide produced mean weight loss of approximately 20.2% of body weight versus 13.7% for semaglutide, a statistically significant difference. Earlier, the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide hitting up to 22.5% weight loss at 72 weeks in people without diabetes. The STEP-1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4mg achieving around 14.9% weight loss at 68 weeks. Tirzepatide works on both GLP-1 and GIP receptors; semaglutide targets GLP-1 alone. That dual mechanism appears to drive the difference in weight loss magnitude.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok GLP-1 content and clinical reality is the treatment of side effects as afterthoughts. Both drugs carry significant gastrointestinal burden: nausea, vomiting, diarrhea, and constipation are common, particularly during dose escalation. In SURMOUNT-5, gastrointestinal adverse events occurred in roughly 79% of tirzepatide participants versus 72% for semaglutide. Creators also rarely mention that neither drug is a standalone solution. The STEP-1 trial found that participants who discontinued semaglutide regained approximately two-thirds of lost weight within a year (Wilding et al., 2022, Diabetes Care). The same rebound pattern is expected with tirzepatide. There is also a persistent misconception that Mounjaro and Zepbound are interchangeable from a coverage standpoint. They use the same active ingredient at identical doses but carry different FDA indications, which has real-world insurance implications that a 60-second TikTok rarely addresses honestly.

What should you actually know?

If you are trying to decide between these two drugs, the clinical evidence now pretty clearly favors tirzepatide on weight loss magnitude, particularly after SURMOUNT-5. But that does not make semaglutide a bad drug. Semaglutide has a longer cardiovascular outcomes track record through the SELECT trial (Lincoff et al., 2023, NEJM), which showed a 20% reduction in major adverse cardiovascular events in people with obesity and established cardiovascular disease. Tirzepatide's cardiovascular outcomes data from SURPASS-CVOT is still maturing. Cost and insurance access are frequently the deciding factor in real clinical practice, not efficacy rankings. Both medications require a legitimate prescription, ongoing medical supervision, and lifestyle support to sustain results. Anyone using social media comparisons as a substitute for a clinical conversation with a prescriber is making a decision with incomplete information, regardless of how good the TikTok production quality is.